growth hormone deficiency

Metabolic and Muscular Impacts of Switching from Daily Somatropin to Weekly Somapacitan in Adult Growth Hormone Deficiency: Real-World Evidence

By MedXY 08/18/2026

Switching from daily somatropin to once-weekly somapacitan in adults with growth hormone deficiency maintains lean mass, improves functional outcomes, but may increase adiposity indices, highlighting a trade-off in metabolic effects during routine care.

Diabetes & Endocrinology news Pediatrics

In Transition-Age Childhood-Onset GH Deficiency, Glucagon Test Results Reflect Pituitary Damage More Than Body Mass Index

By MedXY 05/31/2026

In 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.

Clinical Updates Diabetes & Endocrinology news Specialties

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

By MedXY 07/31/2025

Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.

Clinical Updates news Pediatrics Specialties

FDA Expands Skytrofa Approval to Adults with Growth Hormone Deficiency: Clinical and Practice Implications

By MedXY 07/30/2025

Once-weekly lonapegsomatropin (Skytrofa) is now FDA-approved for adult growth hormone deficiency, offering a more convenient alternative to daily injections with demonstrated efficacy and safety.